Citations

Clear

3030 citation(s) found for "Susan, M".

Association of Genetic Ancestry With Terminal Duct Lobular Unit Involution Among Healthy Women
Sung, Hyuna , Marino, Natascia , Pfeiffer, Ruth M. , Cora, Renata , Figueroa, Jonine D. , Sherman, Mark E. , Gierach, Gretchen L. , Yang, Xiaohong R. , Marino, Natascia , Pfeiffer, Ruth M , Cora, Renata , Figueroa, Jonine D , Sherman, Mark E , Gierach, Gretchen L , Yang, Xiaohong R , Koka, Hela

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 24, 2022 | Volume: 114 | Issue: 10 | Pages: 1420-1424

10.1093/jnci/djac063 | PMID 35333343 Get It

Abstract Reduced age-related terminal duct lobular unit (TDLU) involution has been linked to increased breast cancer risk and triple-negative breast cancer. Associations of TDLU involution levels with race and ethnicity remain incompletely explored. Herein, we examined the association between genetic ancestry and TDLU involution in normal breast tissue donated by 2014 healthy women in the United States. Women of African ancestry were more likely than European women to have increased TDLU counts (odds ratio [OR]trend = 1.36, 95% confidence interval [CI] = 1.07 to 1.74), acini counts per TDLU (OR = 1.47, 95% CI = 1.06 to 2.03), and median TDLU span (ORtrend = 1.44, 95% CI = 1.08 to 1.91), indicating lower involution, whereas East Asian descendants were associated with decreased TDLU counts (ORtrend = 0.52, 95% CI = 0.35 to 0.78) after controlling for potential confounders. These associations are consistent with the racial variations in incidence rates of triple-negative breast cancer in the United States and suggest opportunities for future work examining whether TDLU involution may mediate the racial differences in subtype-specific breast cancer risk.
Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method
Vachon, Celine M. , Murray, Josiah , Allmer, Cristine, Larson, Dirk R. , Kleinstern, Geffen , Kyle, Robert A. , Kumar, Shaji , Murray, David , Larson, Dirk , Sinnwell, Jason P , Dispenzieri, Angela , Slager, Susan L , Kumar, Shaji K , Murray, David L., Murray, Josiah D , Vachon, Celine M. , Norman, Aaron D. , Sinnwell, Jason P. , Dispenzieri, Angela , Visram, Alissa , Rajkumar, S. Vincent , Slager, Susan L.

Mayo Clinic

Blood Advances | March 22, 2022 | Volume: 6 | Issue: 12 | Pages: 3746-3750

10.1182/bloodadvances.2021006201 | PMID 35316833 Get It

Abstract Mass-spectrometry (MS) assays detect lower levels of monoclonal proteins and result in earlier detection of monoclonal gammopathy of undetermined significance (MGUS). We examined heavy chain MGUS prevalence using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS among 3 risk groups, ages 50 or older: 327 African Americans (AA) and 1223 European Americans (EA) from a clinical biobank and 1093 unaffected first-degree relatives (FDR) of patients with hematologic disorders. Age- and sex-adjusted prevalence rates were directly standardized to 2010 United States population. Prevalence ratios were estimated for comparisons of AA and FDR to the EA group using the Poisson distribution. Results were also compared with population-based prevalence using conventional gel-based methods. Risk groups had similar sex and age distributions. MALDI-TOF MGUS prevalence was higher in the AA (16.5% [95% confidence interval (CI), 12.2%, 20.8%]) and FDR (18.3% [95% CI, 16.6%, 21.6%]) than in EA (10.8% [95% CI, 8.8%, 12.7%]), translating to prevalence ratios of 1.73 (95% CI, 1.31, 2.29) and 1.90 (95% CI, 1.55, 2.34), respectively. MALDI-TOF EA prevalence was over threefold higher than conventional estimates but showed similar age trends. Thus, the MALDI-TOF assay found greater numbers with MGUS but similar relative differences by race, family history, and age as prior studies.
Abstract 69: The Effect of Patching in Carotid Endarterectomy (CEA) on Reducing The Risk of Restenosis and Stroke in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)
Malas, Mahmoud B. , Moore, Wesley S. , Lal, Brajesh K. , Hughes, Susan , Voeks, Jenifer H. , Brott, Thomas G.

Mayo Clinic

Stroke | March 20, 2022 | Volume: 45 | Issue: suppl_1 | Pages: No page available

10.1161/str.45.suppl_1.69 Get It

Objective: To compare the perioperative risk of any stroke, death and MI and the long-term risk of re-stenosis and stroke following CEA with patching (a prosthetic or vein patch sutured to the arterial opening to widen the closure) versus CEA with primary closure in CREST. Methods: We included patients who were randomized and underwent CEA in CREST. We compared peri-procedural and 4-year event rates and 2-year restenosis rates, in addition to rates of reoperation between the two groups. Re-stenosis was defined as elevated peak systolic velocity ≥3.0 m/s on carotid duplex US. Treatment differences were assessed using proportional hazard models adjusting for age, sex, and symptomatic status. Results: There were 1,148 patients who underwent CEA (755 {66%} patch; 328 {29%} primary closure). We excluded 43 patients who underwent eversion CEA and 24 patients missing CEA data (5%). There was no significant difference between the two groups with respect to age, sex, race and comorbidities (Table 1). There were significant reductions in the risk of any periprocedural stroke and death (HR 0.35, 95% CI 0.15-0.82, P<0.02), in re-operation (OR 0.33, 95% CI 0.14-0.80, P<0.01), in the 4-year risk of stroke (HR 0.52, 95% CI 0.28-0.97, P<0.04) and in the 2-year risk of re-stenosis (HR 0.26, 95% CI 0.14-0.45, P<0.0001) in the patch compared to the primary closure group (Table 2). Conclusion: Patch closure should be considered for all CEAs because of the association of patch closure with reductions in risk of periprocedural stroke and death, re-operation, and long-term clinical and anatomic durability.
Abstract WP160: A Post-Hoc Assessment of Current Hormone Therapy on Revascularization Risk in Women: The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST)
Mackey, Ariane , Lutsep, Helmi L. , Milot, Geneviève , Voeks, Jenifer H. , Hughes, Susan , Tom, MeeLee , Longbottom, Mary, Sheffet, Alice J., Brott, Thomas G. , Howard, Virginia J.

Mayo Clinic

Stroke | March 20, 2022 | Volume: 44 | Issue: suppl_1 | Pages: No page available

10.1161/str.44.suppl_1.awp160 Get It

Background: Hormone replacement therapy (HRT) was among factors considered in a post-hoc assessment of the risk of revascularization by carotid artery stenting (CAS) or carotid endarterectomy (CEA) in women enrolled in CREST. Methods: Of the 872 women in CREST, 775 (89%) were post-menopausal and current HRT status was known in 739 (95%). The study composite outcome was defined as any stroke, myocardial infarction, or death during the periprocedural period, plus ipsilateral stroke over a 4-year follow-up period. Treatment groups were combined and differences in the composite outcome were assessed by current HRT at baseline. Results: There were 77/739 (10%) current HRT users. HRT users were more likely to be symptomatic at baseline than non-users (65% vs. 52%; p = 0.027), and were less likely to be diabetic (19% vs. 32%; p = 0.024). However, they were similar in most other factors including age, race, hypertension, dyslipidemia, smoking status, and length of follow-up (p > 0.10). There were no (0) periprocedural events among the 77 HRT users while there were 43 (6.5%) events among the 662 non-users (p = 0.017). Among those event-free at the end of the periprocedural period, there was little evidence of an impact of baseline HRT on the risk of ipsilateral stroke with 2 (2.6%) post-procedural events among 77 HRT users and 12 (1.9%) among 619 non-users. Conclusion: We found that women on current HRT have lower periprocedural risk associated with CAS or CEA than non-users, but little difference in risk after the procedural period. The mechanism for this unexpected finding is elusive. We urge caution in the interpretation of this post-hoc observation and encourage replication or refutation by other revascularization studies with similar data.
Abstract 130: Effects of Genetic Inactivation of Amyloid Precursor Protein in Cerebral Microvasculature
Santhanam, Anantha Vijay R., Austin, Susan A., Katušić, Zvonimir S. , d’Uscio, Livius V.

Mayo Clinic

Stroke | March 20, 2022 | Volume: 45 | Issue: suppl_1 | Pages: No page available

10.1161/str.45.suppl_1.130 Get It

Background: Amyloid precursor protein (APP) is expressed in neuronal and non-neuronal tissues in the brain, including cerebrovascular endothelium. However, the physiological role of APP in cerebral vasculature is not completely understood. The present study was designed to determine the effects of inactivation of APP in cerebral microvasculature. Methods: Effect of genetic inactivation of APP was studied both in vitro and in vivo . Cultured human brain microvascular endothelial cells (hBMECs) were incubated with APP-siRNA in vitro , while control-siRNA treated hBMECs served as controls. To study the effect of genetic inactivation of APP in vivo , cerebral microvessels were obtained from APP-deficient (APPKO) mice. Cerebral microvessels from wild-type (C57BL/6) littermates served as controls. Results: Silencing APP expression in hBMECs resulted in selective reduction in endothelial nitric oxide synthase (eNOS) expression (P<0.05, n=6), while expressions of inducible NOS and prostacyclin (PGI2) synthase remained unchanged. Furthermore, loss of APP in hBMECs resulted in significantly increased production (P<0.05, n=5) of superoxide anions, as determined by quantitation of 2-hydroxyethidium from dihydroethidium using HPLC. In line with the results obtained from in vitro studies, cerebral microvessels of APPKO mice also demonstrated increased production of superoxide anions. Furthermore, levels of cGMP, second messenger of endothelial NO, were significantly attenuated in cerebral microvessels of APPKO mice, while levels of cAMP remained unchanged. Conclusions: Our results suggest that genetic inactivation of APP results in oxidative stress and impairment of endothelial NO signaling. We speculate that APP exerts vascular protective effects in the cerebral circulation under physiological conditions.
Abstract P362: Prognostic Value of Troponin in Myocardial Infarction in the Community
Roger, Véronique L. , Bell, Malcolm R. , Weston, Susan A., Jaffe, Allan S. , Jaffe, Allan S.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 4 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.4.suppl_1.ap362 Get It

Troponin is the biomarker of choice for the diagnosis of myocardial infarction (MI) in clinical practice. Data on its value to predict death, while documented in clinical trials, are lacking from community studies. There is little information from population studies of MI on short and long term predictive value of Troponin on death and nonfatal endpoints such as recurrent ischemic events and heart failure. Methods: We evaluated the prognostic value of Troponin T (TnT) among consecutive persons with incident MI in Olmsted County, MN. Results: 1220 persons (mean age 69±15 years, 45% women) experienced an incident MI (20% ST elevation MI) in Olmsted County, MN between 2002 and 2008. Peak TnT value measured at a median of 1 day post-MI was 1.88±4.19 ng/mL (median 0.52 (25%: 0.16, 75%: 1.75)). After 1.27 years of follow-up, 294 deaths occurred, 360 recurrent ischemic events (recurrent MI or hospitalized unstable angina) and 345 episodes of heart failure. Associations between clinical events and TnT tertiles are shown in the table . Conclusions: In the community, the magnitude of TnT elevation is predictive of recurrent ischemic events, heart failure and early death. It is not associated with long-term mortality. Hazard ratio compared to lowest TnT tertile, 95%CI and p value Adjusted for age, sex and comorbidity Outcome All events Events within 30 days Events among 30 day survivors Death TnT tertile 2 TnT tertile 3 p-value 1.02 (0.78-1.33) 1.15 (0.85-1.57) 0.64 0.64 (0.38-1.06) 1.59 (0.98-2.57) 0.004 1.24 (0.90-1.69) 0.93 (0.62-1.38) 0.26 Recurrent ischemic events TnT tertile 2 TnT tertile 3 p-value 1.45 (1.12-1.88) 1.70 (1.29-2.24) <0.001 1.45 (0.96-2.19) 2.07 (1.37-3.12) 0.002 1.46 (1.05-2.04) 1.45 (1.00-2.10) 0.049 Heart failure TnT tertile 2 TnT tertile 3 p-value 1.03 (0.78-1.36) 2.10 (1.58-2.78) <0.001 0.94 (0.68-1.29) 2.10 1.54-2.87) <0.001 1.38 (0.79-2.41) 2.19 (1.14-4.21) 0.067
Abstract P361: Heart Failure and Fractures: A Community Study
Melton, L. Joseph, Weston, Susan A., Roger, Véronique L. , Gerber, Yariv

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 4 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.4.suppl_1.ap361 Get It

Background: Recent findings suggest a role for heart failure in the etiology of osteoporotic fractures, but the nature of the relationship is unclear and community data are lacking. Methods and Results: We conducted a community-based case-control study comparing prior osteoporotic fractures among Olmsted County, Minnesota, residents newly diagnosed with heart failure in 1979-2002 (cases) to age- and sex-matched community controls without heart failure (961 pairs; mean age: 76 years; 54% women). Subjects were then followed forward in time to July 2009 to evaluate the risk of fracture subsequent to the heart failure diagnosis. Prior fractures were more frequent in heart failure cases than controls: 23% versus 19%, P =0.02; adjusted odds ratio (OR) for any osteoporotic fracture 1.39 (95% CI: 1.07-1.81). This was related to hip fractures (OR: 1.82; 95% CI: 1.25-2.66) with little or no association with other fractures. Over a mean follow-up of 7.5 years, 536 new osteoporotic fractures occurred in 444 individuals. The adjusted fracture risk was higher among heart failure patients compared to controls (hazard ratio [HR]: 1.32; 95% CI: 0.98-1.79), again largely attributable to hip fractures (HR: 1.58; 95% CI: 1.03-2.41). Conclusions: Patients diagnosed with heart failure experience an excess risk of fractures both before and after the diagnosis of heart failure, which is related to hip fractures. These findings suggest common underlying and co-occurring mechanisms for heart failure and hip fracture and underscore the crucial importance of preventing falls in elderly heart failure patients.
Abstract P114: Longitudinal Use of Echocardiography After Heart Failure Diagnosis in the Community
Redfield, Margaret M. , Weston, Susan A., Killian, Jill M. , Roger, Véronique L. , Dunlay, Shannon M.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 4 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.4.suppl_1.ap114 Get It

Background: Echocardiography is an important component of the assessment of patients with heart failure (HF). However, its longitudinal use after initial HF diagnosis has not been evaluated. Methods: We studied patterns of echocardiogram use after HF diagnosis among a random sample of validated incident HF cases in Olmsted County, Minnesota, from 1987 to 2006. Results: Among 1472 HF patients (mean age 76.0 years, 45% male), 4817 echocardiograms were obtained over a mean follow-up of 5.1 years. The majority were transthoracic (n=3952, 82%), with fewer transesophageal (n=604, 13%) and stress (n=250, 5%) studies obtained. Most patients died during follow-up (n=1126, 76%), and thus had their entire lifetime after HF diagnosis captured. The number of echocardiograms per person ranged from 0-38 (Figure) with a median (25 th , 75 th percentile) of 2 (1, 4). The mean rate of echocardiograms obtained per 10 years of follow-up was 6.4, and increased over time with mean echocardiograms per 10 years follow-up of 4.9, 5.9, 7.2, and 7.8 for persons diagnosed from 1987-1991, 1992-96, 1997-2001, and 2002-06, respectively (p for trend <0.001). Men had echocardiograms more frequently than women (7.2 vs. 5.7 per 10 person years follow-up, p<0.001). Patients who were younger at diagnosis had more frequent echocardiography with rates of 7.1, 6.8, and 5.2 per 10 years follow-up for those who were <70 years, 70-79 years, and 80 years or older at diagnosis (p for trend <0.001). Conclusions: Most patients have multiple echocardiograms performed after HF diagnosis, and echocardiography use in patients with HF has increased over time. Men and younger patients have higher rates of use after HF diagnosis.
Abstract 10603: Risk Factors for Development of Advanced Heart Failure: A Population-Based Study
Subramaniam, Anna , Weston, Susan A., Killian, Jill M. , Schulte, Philip, Roger, Véronique L. , Redfield, Margaret M. , Blecker, Saul , Dunlay, Shannon M.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10603 Get It

Introduction: Some patients with heart failure (HF) will go on to develop advanced HF, characterized by severe HF symptoms despite attempts to optimize medical therapy. Our understanding of advanced HF at a population level remains limited. The goals of this study were to determine the risk of developing advanced HF in patients with newly diagnosed HF, identify risk factors for developing advanced HF, and evaluate the impact of advanced HF on outcomes. Methods: This was a population-based, retrospective cohort study of Olmsted County, Minnesota residents with a new clinical diagnosis of HF between 2007-2017. The primary outcome was development of advanced HF, defined using the 2018 European Society of Cardiology Criteria. Risk factors for development of advanced HF from the time of incident HF diagnosis were examined using cause-specific Cox proportional hazard regression models. The associations of development of advanced HF with risks of hospitalization and mortality were examined using Andersen-Gill and Cox models, respectively, with advanced HF treated as a time dependent covariate. Results: There were 4597 residents with incident HF from 2007 to 2017. The cumulative incidence of advanced HF was 6.0%, 9.1%, and 11.5% at 2, 4, and 6 years after incident HF diagnosis. Characteristics independently associated with development of advanced HF included older age, male sex, diabetes, chronic obstructive pulmonary disease, peripheral vascular disease, lower serum sodium, worse right ventricular function, left atrial enlargement, higher estimated filling pressures, and higher right ventricular systolic pressure (p<0.05 for each). Development of advanced HF was associated with increased risks of all-cause hospitalization (adjusted HR 3.00; 95% CI 2.65-3.41, p<0.001), HF hospitalization (HR 10.24, 95% CI 8.67-12.10), all-cause mortality (HR 5.00, 95% CI 4.46-5.59, p<0.001), and cardiovascular mortality (HR 7.84, 95% CI 6.74-9.12). Conclusions: In this population-based study, clinical, laboratory and echocardiographic characteristics at the time of incident HF diagnosis were associated with future risk of advanced HF. Development of advanced HF was associated with markedly increased morbidity and mortality.
Abstract 10515: Deep Phenotyping of Heart Failure with Machine Learning: An Echocardiographic Community Study
Weston, Susan A., Jiang, Ruoxiang , Joo, Jungnam , Manemann, Sheila M., Roger, Véronique L. , Larson, Nicholas B. , Michelena, Héctor I. , Bielinski, Suzette J. , Chamberlain, Alanna M.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10515 Get It

Introduction: Heart failure (HF) is a clinical syndrome with high mortality. Left ventricular ejection fraction (EF) determines clinical phenotyping and HF is classified most often as preserved (HFpEF) or reduced (HFrEF) EF. The importance of expanding phenotyping beyond EF is recognized. We hypothesized that machine learning applied to echocardiography will provide information important for deep phenotyping. Methods: We collected clinical and echo data in a HF community cohort between 2013 and 2017. Unsupervised clustering was applied to 23 echo variables using partitioning around medoids (PAM), with Gower dissimilarity used to address the mixed variable types. Proportional hazards regression examined the association between cluster assignment and death. Results: We identified 4978 persons with HF [mean age 73.9 years (SD 13.9), 47% women] with echocardiography within 6 months of diagnosis. We identified 2 primary clusters using echo variables, as depicted using t-Distributed Stochastic Neighbor Embedding (t-SNE) applied to the dissimilarity matrix (Figure). Diastolic function variables exhibited the largest differences by clusters as shown by absolute standardized differences (Table). After 3.2 + 1.9 years of follow up, 2001 deaths occurred. Assignment to cluster 2 was associated with a near 20% excess risk of death independent of age, sex, comorbidity, and EF [HR 1.17 (1.07, 1.28) p<0.001]. Conclusions: Unsupervised clustering applied to echocardiography in a large community HF cohort identified 2 distinct clusters, which defined HF subgroups with different characteristics and were independently associated with risk of death.